# US 2015/0148758 A1 · Mirtazapine-containing transdermally-absorbable skin-adhesive preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148758 A1
- Document ID: US20150148758A1
- Status: Published application
- Kind: A1
- Application number: 14/404,730
- Filed: 2013-05-14
- Published: 2015-05-28
- Earliest claimed: 2012-06-05
- Assignees: Yutoku Pharmaceutical Industries Co., Ltd.
- Applicants: Yutoku Pharmaceutical Industries Co., Ltd.,
- Inventors: Makoto Yoshitake; Kenta Nishimura
- Web page: https://patentgrep.com/patent/US20150148758A1

## CPC

- A61K 9/7053: {obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene}
- A61K 9/7061: {Polyacrylates}
- A61K 9/7076: {the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins}
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The purpose is to provide a mirtazapine-containing transdermal patch capable of suppressing deposition of a crystalline component derived from mirtazapine, deterioration in sense of use, and deterioration in adhesiveness to the skin. The transdermal patch contains a support, a drug-containing layer and a release liner, and the drug-containing layer contains mirtazapine and an organic acid.

## Claims

### Claim 1

A transdermal patch comprising a support, a drug-containing layer, and a release liner, wherein the drug-containing layer comprises mirtazapine and an organic acid.

### Claim 2 (depends on 1)

The transdermal patch according to claim 1, wherein the drug-containing layer comprises 3%-30% of mirtazapine by mass relative to the drug-containing layer.

### Claim 3 (depends on 2)

The transdermal patch according to claim 2, wherein the drug-containing layer comprises 5%-25% of mirtazapine by mass relative to the drug-containing layer.

### Claim 4 (depends on 1)

The transdermal patch according to claim 1, wherein the organic acid is an organic acid comprising 2 to 18 carbon atoms.

### Claim 5 (depends on 4)

The transdermal patch according to claim 4, wherein the organic acid comprising 2 to 18 carbon atoms is at least one selected from the group consisting of glycolic acid, citric acid, caprylic acid, azelaic acid, capric acid, undecenoic acid, lauric acid, myristic acid, isostearic acid, stearic acid, oleic acid, and lactic acid.

### Claim 6 (depends on 1)

The transdermal patch according to claim 1, wherein the drug-containing layer comprises 2%-30% of the organic acid by mass relative to the drug-containing layer.

### Claim 7 (depends on 1)

The transdermal patch according to claim 1, wherein the drug-containing layer comprises 3%-24% of the organic acid by mass relative to the drug-containing layer.

### Claim 8 (depends on 1)

The transdermal patch according to claim 1, wherein the organic acid is present in the drug-containing layer in an amount of 0.3-11.0 times by mole the amount of mirtazapine.

### Claim 9 (depends on 8)

The transdermal patch according to claim 8, wherein the organic acid is present in the drug-containing layer in an amount of 0.5-9.0 times by mole the amount of mirtazapine.

### Claim 10 (depends on 1)

The transdermal patch according to claim 1, wherein drug-containing layer further comprises, as a base ingredient, at least one adhesive ingredient selected from the group consisting of a rubber-type adhesive base, an acrylic polymer, and a silicone polymer.

### Claim 11 (depends on 10)

The transdermal patch according to claim 10, wherein the adhesive ingredient is a rubber-type adhesive base and/or an acrylic polymer.

### Claim 12 (depends on 10)

The transdermal patch according to claim 10, wherein the drug-containing layer comprises 20%-91% of the adhesive ingredient by mass relative to the drug-containing layer.

### Claim 13 (depends on 1)

The transdermal patch according to claim 1, wherein the drug-containing layer further comprises, as a tackifier, at least one selected from the group consisting of a rosin derivative and an aliphatic saturated hydrocarbon resin.

### Claim 14 (depends on 13)

The transdermal patch according to claim 13, wherein the tackifier is a rosin derivative.

### Claim 15 (depends on 13)

The transdermal patch according to claim 13, wherein the drug-containing layer comprises 8%-46% of the tackifier by mass relative to the drug-containing layer.

### Claim 16

A method for producing a transdermal patch comprising a support, a drug-containing layer, and a release liner, the method comprising adding mirtazapine and an organic acid into the drug-containing layer.

### Claim 17

A method for suppressing deposition of crystals of mirtazapine, the method comprising, in a transdermal patch comprising a support, a drug-containing layer, and a release liner, adding mirtazapine and an organic acid into the drug-containing layer.
